Foresite, which is a growth equity firm in the healthcare sector recently made an announcement about a new venture partner. As per Drewaltizer, the new venture partner is Molly He, Ph.D. Dr. He has over 15 years of experience in the pharmaceutical industry. He has worked at Illumina where she held the position of senior director.
According to Businesswire, Dr. He is a welcome addition to the team. She is one of the most respected scientific minds in the field of next-generation sequencing. The CEO added that Dr. He’s expertise in the field of drug development and genomics and her excellent record of accomplishment in leadership would prove to be invaluable to Foresite. The company is currently making an effort to diversify and expand its portfolio.
Her Previous Roles
Dr. He was previously working as the senior director at Illumina in charge of scientific research. She was in charge of the firms’ protein reagent improvements and innovation. Before joining Illumina, she worked at Pacific Biosciences as the head of protein sciences. She was in charge of the development of protein reagent for the firms, single molecular real-time sequencing chemistry.
Sr. He spent about a decade of her career in the pharmaceutical industry. During that time, she focused mainly on structural-based designed of small molecule drugs and antibody for cancer treatment and immune illnesses. She is a holder of Bachelor if Biochemistry from Nankai University. Dr. He also holds a PH.D. From the University of California, LA in protein biophysics. She has authored over 20 published papers. Additionally, she is a holder of over 20 patents application and patents in the area of personalized medicine and next-generation sequencing. Sourced info: Insidermonkey.com
About Jim Tananbaum
Jim Tananbaum has more than two decades of experience in the pharmaceutical industry. Some of the firms that he has been part of our Sierra Ventures and Prospect Venture Partners II and III. Some of his major investments are Healtheon, Amerigroup, Jazz Pharmaceuticals, and Amira Pharmaceuticals.
Jim is a holder of a B.S.E.E. and a BS from Yale. Additionally, he holds an MD from Harvard Medical School. Other academic credentials are an MBA from Harvard business School and an MS from MIT.